The US based CDMO, SK pharmteco, and the German preclinical gene therapy development company, AaviGen, have entered into a multi-year manufacturing agreement under which SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead heart failure gene therapy product, AVG-101.

AaviGen’s proprietary heart-specific adeno-associated viral vector technology has reportedly enabled development of therapies that target and reverse the underlying molecular causes of heart muscle dysfunction. Aavigen notes that SK pharmteco’s recent capacity investments and experience in adeno-associated viral-based gene therapies were key factors in selecting the company as a manufacturing partner.